查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1877403

注射用细胞毒性药物市场：依药物来源、适应症、最终用户、给药途径、药物类别、国家及地区划分－全球产业分析、市场规模、市场占有率及2025-2032年预测

Injectable Cytotoxic Drugs Market, By Drug Origin, By Indication, By End User, By Route of Administration, By Drug Class, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 376 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年註射用细胞毒性药物市场规模为 196.25 亿美元，从 2025 年到 2032 年以 6.50% 的复合年增长率成长。

注射用细胞毒性药物市场是指生产、分销和销售用于治疗癌症的药物（特别是注射给药的药物）的製药业。细胞毒性药物透过抑制细胞分裂来杀死癌细胞，最终导致癌细胞死亡。

注射用细胞毒性药物市场－市场动态

类风湿性关节炎盛行率上升推动市场成长

类风湿性关节炎发病率的上升预计将推动注射用细胞毒性药物市场的未来成长。类风湿性关节炎是一种慢性自体免疫疾病，其特征是持续的关节发炎、疼痛以及最终的关节损伤。随着人口老化，类风湿性关节炎的发生率不断上升，导致基因突变和免疫系统功能障碍的风险增加，而这些因素都会加剧病情。注射用细胞毒性药物透过靶向快速分裂的细胞并抑制过度活跃的免疫反应来帮助治疗类风湿性关节炎，从而延缓疾病进展并缓解症状。例如，根据澳洲独立法定机构－澳洲健康与福利研究所的数据，2024年6月，类风湿性关节炎导致1,322人死亡，相当于每10万人中有5.1人死亡，占2022年所有死亡人数的0.7%。 2023年，类风湿性关节炎占总疾病负担的2.0%，占所有肌肉骨骼疾病总负担的16%。因此，类风湿性关节炎盛行率的上升正在推动注射用细胞毒性药物产业的成长。

注射用细胞毒性药物市场細項分析：

全球注射用细胞毒性药物市场细分为药物来源、适应症、最终用户、给药途径、药物类别和地区。

根据药物来源，细胞毒性药物市场可分为三大类：仿製药、品牌药和复方细胞毒性製剂（小众市场）。预计仿製药在註射用细胞毒性药物市场将实现显着成长。随着全球癌症负担的持续加重，越来越多的医疗机构正在考虑使用仿製药来提高药物的可及性和可负担性。仿製药注射用细胞毒性药物与品牌药具有相同的疗效，但价格更低，因此对于公共医疗机构和患者而言，都是更经济实惠的选择。政府和保险公司也透过定向广告鼓励人们使用仿製药，以降低医疗成本，尤其对于长期癌症患者而言。

根据最终用户，市场可分为五大类：医院、门诊手术中心 (ASC)、癌症及专科诊所、家庭护理机构（配备行动输液单元）和政府肿瘤中心。医院在註射用细胞毒性药物市场中占据主导地位。医院的肿瘤科或癌症中心拥有先进的治疗手段，例如注射化疗。这些机构遵循高风险细胞毒性药物的给药方案，强调住院环境中常见的监测和紧急支持系统。医院鼓励采用多学科治疗方法，由肿瘤内科医生、放射科医生和病理学家共同协作，凸显了注射用细胞毒性药物给药的重要性。医院是细胞毒性治疗的首选机构，因为它们可以在院内处理副作用和併发症。

注射用细胞毒性药物市场—地域性洞察

北美在全球注射型细胞毒性药物市场占据主导地位。该地区成熟的肿瘤治疗体系使得先进的细胞毒性治疗得以广泛应用，同时也促进了免疫疗法和放射疗法等新兴疗法的发展。此外，癌症筛检和早期诊断的普及也使得更多患者能够在疾病早期接受注射型细胞毒性药物治疗，从而改善治疗效果并提升市场需求。

预计亚太地区在预测期内将以最快的复合年增长率成长，主要受癌症病例增加、医疗基础设施进步以及政府肿瘤防治政策支持等因素的推动。该地区市场的扩张得益于政府医疗保健计划、与製药公司的合作以及肿瘤药物的本地化生产，从而提高了药物的可及性。医疗保健支出的增加和医疗保险覆盖率的提高也改善了患者获得优质医疗服务的机会。

注射用细胞毒性药物市场－竞争格局：

在註射用细胞毒性药物市场，专注于肿瘤和化疗的大型製药公司竞争异常激烈。罗氏控股、赛诺菲、百时美施贵宝、费森尤斯卡比和迈兰（Viatris）是市场领导者。这些公司在药物研发、全球供应和策略联盟方面均处于领先地位，以拓展其肿瘤产品组合。此外，全球癌症发生率的上升，尤其是在北美和亚太等主要市场，以及注射疗法可及性的提高，都加剧了市场竞争。各企业在获得监管部门批准、推出仿製药以及扩大生产规模（尤其是在医院药房管道）方面的能力，是区分彼此的关键因素。

目录

第一章：注射用细胞毒性药物市场概述

  • 研究范围
  • 市场估算年份

第二章：执行概要

  • 市集
    • 注射用细胞毒性药物市场概览（依药物来源划分）
    • 注射用细胞毒性药物市场概况（依适应症划分）
    • 注射用细胞毒性药物市场按最终用户分類的概况
    • 注射用细胞毒性药物市场概览（依给药途径划分）
    • 注射用细胞毒性药物市场概览（按药物类别划分）
    • 各国注射用细胞毒性药物市场概况
    • 注射用细胞毒性药物市场区域概览
  • 竞争洞察

第三章：注射用细胞毒性药物市场主要趋势

  • 注射用细胞毒性药物市场驱动因素
    • 市场驱动因素的影响分析
  • 注射用细胞毒性药物市场限制因素
    • 市场限制因素的影响分析
  • 注射用细胞毒性药物市场机会
  • 注射用细胞毒性药物市场未来趋势

第四章：注射用细胞毒性药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 规范架构分析

第五章：注射用细胞毒性药物市场：地缘政治紧张局势升级的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：注射用细胞毒性药物市场概况

  • 注射用细胞毒性药物市占率分析，2024年
  • 主要製造商细分数据
    • 知名球员分析
    • 新兴参与者分析

第七章：注射用细胞毒性药物市场－依药物来源划分

  • 概述
    • 按药物来源分類的细分市场份额分析
      • 复合细胞毒性製剂（利基）
      • 通用细胞毒性药物
      • 品牌细胞毒性药物

第八章：注射用细胞毒性药物市场－依适应症划分

  • 概述
    • 按指标分類的细分市场占有率分析
    • 膀胱癌和前列腺癌
    • 乳癌
    • 血液系统恶性肿瘤
    • 卵巢癌和子宫颈癌
    • 胰臟癌和肝癌
    • 肺癌
    • 大肠直肠癌
    • 其他（肉瘤、头颈部、胃部）

第九章：注射用细胞毒性药物市场－以最终用户划分

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 门诊手术中心（ASC）
    • 癌症及专科诊所
    • 医院
    • 居家护理环境（配备行动输液车）
    • 政府肿瘤中心

第十章：注射用细胞毒性药物市场－依给药途径划分

  • 概述
    • 按指标分類的细分市场占有率分析
    • 肌肉内注射（IM）
    • 腹腔内（用于HIPEC方案）
    • 鞘内注射
    • 静脉注射/输液
    • 皮下注射（适用于特定药物）
    • 腹腔内（用于HIPEC方案）

第十一章：注射用细胞毒性药物市场－依药物类别划分

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 植物生物碱
    • 细胞毒性抗体
    • 抗代谢物
    • 烷化药物
    • 其他的

第十二章：注射用细胞毒性药物市场－依地域划分

  • 介绍
    • 按地域分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美注射用细胞毒性药物主要生产商
    • 北美市场规模及预测（按国家/地区划分）
    • 北美市场规模及预测（按药物来源划分）
    • 北美市场规模及预测（依适应症划分）
    • 北美市场规模及预测（依最终用户划分）
    • 北美市场规模及预测（依给药途径划分）
    • 北美市场规模及预测（按药物类别划分）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲注射用细胞毒性药物主要生产商
    • 欧洲市场规模及预测（按国家/地区划分）
    • 欧洲市场规模及预测（依药物来源划分）
    • 欧洲市场规模及预测（依适应症划分）
    • 欧洲市场规模及预测（依最终用户划分）
    • 欧洲市场规模及预测（依给药途径划分）
    • 欧洲市场规模及预测（按药物类别划分）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区
    • 概述
    • 亚太地区注射用细胞毒性药物主要生产商
    • 亚太市场规模及预测（依国家/地区划分）
    • 亚太地区市场规模及预测（依药物来源划分）
    • 亚太地区市场规模及预测（依适应症划分）
    • 亚太市场规模及预测（依最终用户划分）
    • 亚太地区市场规模及预测（依给药途径划分）
    • 亚太地区市场规模及预测（依药物类别划分）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲注射用细胞毒性药物主要生产商
    • 拉丁美洲市场规模及预测（按国家/地区划分）
    • 拉丁美洲市场规模及预测（按药物来源划分）
    • 拉丁美洲市场规模及预测（依适应症划分）
    • 拉丁美洲市场规模及预测（按最终用户划分）
    • 拉丁美洲市场规模及预测（依给药途径划分）
    • 拉丁美洲药物类别规模及预测
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲注射细胞毒性药物主要生产商
    • 中东和非洲市场规模及预测（按国家/地区划分）
    • 中东和非洲市场规模及预测（按药物来源划分）
    • 中东和非洲市场规模及预测（按适应症划分）
    • 中东和非洲市场规模及预测（按最终用户划分）
    • 中东和非洲市场规模及预测（按给药途径划分）
    • 中东和非洲市场规模及预测（按药物类别划分）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 中东和非洲其他地区

第十三章：主要供应商分析－注射用细胞毒性药物产业

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • Johnson and Johnson Services Inc.
    • Roche Holding AG
    • Sanofi SA
    • Merck & Co. Inc.
    • Bristol-Myers Squibb
    • Intas Pharmaceuticals Ltd.
    • Natco Pharma
    • Zydus Lifesciences Ltd.
    • Fresenius Kabi
    • Mylan NV (Viatris)
    • Hikma Pharmaceuticals PLC
    • Pfizer Inc.
    • Novartis AG (Sandoz - generics)
    • Eli Lilly and Company
    • Dr. Reddy's Laboratories
    • Sun Pharmaceutical Industries Ltd.
    • Cipla Ltd.
    • Aurobindo Pharma
    • Accord Healthcare
    • Hospira (a Pfizer company)
    • Teva Pharmaceutical Industries Ltd.
    • Amneal Pharmaceuticals
    • Others

第十四章：360度分析师视角

第十五章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5727

Injectable Cytotoxic Drugs Market size was valued at US$ 19,625 Million in 2024, expanding at a CAGR of 6.50% from 2025 to 2032.

The injectable cytotoxic drugs market is the pharmaceutical industry that produces, distributes, and sells drugs used to treat cancer, specifically those administered via injection. Cytotoxic drugs are used to kill cancer cells by inhibiting cell division, causing the cells to die.

Injectable Cytotoxic Drugs Market- Market Dynamics

Rising Prevalence of Rheumatoid Arthritis Propels Market Growth

The rising incidence of rheumatoid arthritis is expected to drive future growth in the injectable cytotoxic drugs market. Rheumatoid arthritis is a chronic autoimmune disorder characterized by ongoing joint inflammation, pain, and eventual joint damage. Rheumatoid arthritis is becoming more common as the population ages, increasing the risk of genetic mutations and immune system dysfunction that contribute to the condition. Injectable cytotoxic drugs help treat rheumatoid arthritis by targeting rapidly dividing cells and suppressing overactive immune responses, which slows disease progression and alleviates symptoms. For instance, according to the Australian Institute of Health and Welfare, an independent statutory agency based in Australia, rheumatoid arthritis was responsible for 1,322 deaths in June 2024, equating to 5.1 deaths per 100,000 people, and 0.7% of all deaths in 2022. It accounted for 2.0% of the overall disease burden and 16% of the total burden from all musculoskeletal conditions in 2023. As a result, the rising prevalence of rheumatoid arthritis is fueling the growth of the injectable cytotoxic drug industry.

Injectable Cytotoxic Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.50% over the forecast period (2025-2032)

Based on Drug Origin segmentation, Generic cytotoxic drugs are expected to grow rapidly in the injectable cytotoxic drug market.

Based on Indication segmentation, the hematological malignancies segment is expected to grow at the fastest rate in the injectable cytotoxic drugs market.

Based on End User segmentation, Hospitals is the leading End User in 2025

Based on Route of Administration segmentation, intravenous injection/infusion is the leading Route of Administration in 2025

Based on Drug Class segmentation, alkylating is predicted to show maximum market share in the year 2025

On the basis of region, North America is the leading revenue generator in 2025

Injectable Cytotoxic Drugs Market- Segmentation Analysis:

The Global Injectable Cytotoxic Drugs Market is segmented by Drug Origin, Indication, End User, Route of Administration, Drug Class, and Region.

The market is divided into three categories based on Drug Origin: Generic Cytotoxic Drugs, Branded Cytotoxic Drugs, and Compounded Cytotoxic Preparations (niche). Generic cytotoxic drugs are expected to experience significant growth in the injectable cytotoxic drugs market. With the global cancer burden steadily increasing, a growing number of healthcare systems are looking into using generics to improve affordability and accessibility. Generic injectable cytotoxic drugs provide the same therapeutic benefits as their brand counterparts at a lower cost, making them an affordable option for both public healthcare providers and patients. Governments and insurance companies also use targeted advertising to encourage people to use generic drugs in order to reduce healthcare costs, particularly for long-term cancer patients.

The market is divided into five categories based on End User: Hospitals, Ambulatory Surgical Centers (ASCs), Cancer & Specialty Clinics, Homecare Settings (with mobile infusion units), and Government Oncology Centers. The hospital segment dominates the injectable cytotoxic drugs market. Oncology departments or cancer centers in hospitals have advanced treatments such as injectable chemotherapy. These facilities follow high-risk cytotoxic drug administration protocols, emphasizing monitoring and emergency support systems found in inpatient settings. Hospitals encourage multidisciplinary treatment approaches in which medical oncologists, radiologists, and pathologists collaborate, emphasising the importance of administering injectable cytotoxic drugs. Hospitals are the preferred choice for cytotoxic treatments because they can manage side effects and complications on-site.

Injectable Cytotoxic Drugs Market- Geographical Insights

North America dominates the global injectable cytotoxic drugs market. The advanced cytotoxic treatment area is widely adopted because the region's mature oncology ecosystem allows for widespread adoption of advanced treatment categories, as well as emerging solutions such as immunotherapy and radiation, among others. The prevalence of cancer screening and early diagnosis also contributes to increased access to injections for patients who receive cytotoxic drugs earlier in the course of the disease, improving treatment outcomes and increasing demand.

The Asia Pacific is expected to grow at the fastest CAGR during the forecast period, driven by rising cancer cases, advancements in healthcare infrastructure, and supportive government oncology policies. The regional market's expansion is being driven by increased drug availability through government healthcare programs, collaborations with pharmaceutical companies, and local production of oncology medicines. Increased healthcare spending and rising health insurance penetration improve patient access to quality medical care.

Injectable Cytotoxic Drugs Market- Competitive Landscape:

In the injectable cytotoxic drugs market, major pharmaceutical companies focused on oncology and chemotherapy compete fiercely. Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb, Fresenius Kabi, and Mylan N.V. (Viatris) are among the market leaders. These companies are pioneers in drug development, global supply, and strategic alliances to broaden their oncology portfolios. Moreover, the combination of rising cancer incidence worldwide, particularly in key markets such as North America and Asia-Pacific, and increased access to injectable therapies is driving competition. Players are distinguished by their ability to obtain regulatory approvals, launch generic products, and scale manufacturing, particularly in hospital pharmacy channels.

Recent Developments:

In February 2024, Novartis agreed to pay 2.7 billion Euros in a voluntary public takeover offer to acquire MorphoSys AG, a global, German-based biopharmaceutical company that produces oncology drugs.

In May 2023, Innovent Biologics and Inc. and Eli Lilly and Company jointly announced the National Medical Products Administration of China has approved the supplemental New Drug Application (sNDA) for TYVYT (sintilimab injection) when used alongside bevacizumab and chemotherapy (pemetrexed and cisplatin) for individuals with non-squamous non-small cell lung cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Johnson and Johnson Services Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Merck & Co. Inc.
  • Bristol-Myers Squibb
  • Intas Pharmaceuticals Ltd.
  • Natco Pharma
  • Zydus Lifesciences Ltd.
  • Fresenius Kabi
  • Mylan N.V. (Viatris)
  • Hikma Pharmaceuticals PLC
  • Pfizer Inc.
  • Novartis AG (Sandoz - generics)
  • Eli Lilly and Company
  • Dr. Reddy's Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Aurobindo Pharma
  • Accord Healthcare
  • Hospira (a Pfizer company)
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals
  • Others

GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY DRUG ORIGIN- MARKET ANALYSIS, 2019 - 2032

  • Compounded Cytotoxic Preparations (niche)
  • Generic Cytotoxic Drugs
  • Branded Cytotoxic Drugs

GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Bladder & Prostate Cancer
  • Breast Cancer
  • Hematological Malignancies
  • Ovarian & Cervical Cancer
  • Pancreatic & Liver Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Others (Sarcoma, Head & Neck, Gastric)

GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Ambulatory Surgical Centers (ASCs)
  • Cancer & Specialty Clinics
  • Hospitals
  • Homecare Settings (with mobile infusion units)
  • Government Oncology Centers

GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intramuscular (IM)
  • Intraperitoneal (used in HIPEC protocols)
  • Intrathecal
  • Intravenous (IV) Injection/Infusion
  • Subcutaneous (for select agents)
  • Intraperitoneal (used in HIPEC protocols)

GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Plant Alkaloids
  • Cytotoxic Antibodies
  • Antimetabolites
  • Alkylating Drugs
  • Others

GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Injectable Cytotoxic Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Injectable Cytotoxic Drugs Market Snippet by Drug Origin
    • 2.1.2. Injectable Cytotoxic Drugs Market Snippet by Indication
    • 2.1.3. Injectable Cytotoxic Drugs Market Snippet by End User
    • 2.1.4. Injectable Cytotoxic Drugs Market Snippet by Route of Administration
    • 2.1.5. Injectable Cytotoxic Drugs Market Snippet by Drug Class
    • 2.1.6. Injectable Cytotoxic Drugs Market Snippet by Country
    • 2.1.7. Injectable Cytotoxic Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Injectable Cytotoxic Drugs Key Market Trends

  • 3.1. Injectable Cytotoxic Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Injectable Cytotoxic Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Injectable Cytotoxic Drugs Market Opportunities
  • 3.4. Injectable Cytotoxic Drugs Market Future Trends

4. Injectable Cytotoxic Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Injectable Cytotoxic Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Injectable Cytotoxic Drugs Market Landscape

  • 6.1. Injectable Cytotoxic Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Injectable Cytotoxic Drugs Market - By Drug Origin

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Origin, 2024 & 2032 (%)
      • 7.1.1.1. Compounded Cytotoxic Preparations (niche)
      • 7.1.1.2. Generic Cytotoxic Drugs
      • 7.1.1.3. Branded Cytotoxic Drugs

8. Injectable Cytotoxic Drugs Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 8.1.2. Bladder & Prostate Cancer
    • 8.1.3. Breast Cancer
    • 8.1.4. Hematological Malignancies
    • 8.1.5. Ovarian & Cervical Cancer
    • 8.1.6. Pancreatic & Liver Cancer
    • 8.1.7. Lung Cancer
    • 8.1.8. Colorectal Cancer
    • 8.1.9. Others (Sarcoma, Head & Neck, Gastric)

9. Injectable Cytotoxic Drugs Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 9.1.2. Ambulatory Surgical Centers (ASCs)
    • 9.1.3. Cancer & Specialty Clinics
    • 9.1.4. Hospitals
    • 9.1.5. Homecare Settings (with mobile infusion units)
    • 9.1.6. Government Oncology Centers

10. Injectable Cytotoxic Drugs Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 10.1.2. Intramuscular (IM)
    • 10.1.3. Intraperitoneal (used in HIPEC protocols)
    • 10.1.4. Intrathecal
    • 10.1.5. Intravenous (IV) Injection/Infusion
    • 10.1.6. Subcutaneous (for select agents)
    • 10.1.7. Intraperitoneal (used in HIPEC protocols)

11. Injectable Cytotoxic Drugs Market - By Drug Class

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 11.1.2. Plant Alkaloids
    • 11.1.3. Cytotoxic Antibodies
    • 11.1.4. Antimetabolites
    • 11.1.5. Alkylating Drugs
    • 11.1.6. Others

12. Injectable Cytotoxic Drugs Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Injectable Cytotoxic Drugs Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Injectable Cytotoxic Drugs Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Injectable Cytotoxic Drugs Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Injectable Cytotoxic Drugs Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Injectable Cytotoxic Drugs Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Injectable Cytotoxic Drugs Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Johnson and Johnson Services Inc.
    • 13.2.2. Roche Holding AG
    • 13.2.3. Sanofi S.A.
    • 13.2.4. Merck & Co. Inc.
    • 13.2.5. Bristol-Myers Squibb
    • 13.2.6. Intas Pharmaceuticals Ltd.
    • 13.2.7. Natco Pharma
    • 13.2.8. Zydus Lifesciences Ltd.
    • 13.2.9. Fresenius Kabi
    • 13.2.10. Mylan N.V. (Viatris)
    • 13.2.11. Hikma Pharmaceuticals PLC
    • 13.2.12. Pfizer Inc.
    • 13.2.13. Novartis AG (Sandoz - generics)
    • 13.2.14. Eli Lilly and Company
    • 13.2.15. Dr. Reddy's Laboratories
    • 13.2.16. Sun Pharmaceutical Industries Ltd.
    • 13.2.17. Cipla Ltd.
    • 13.2.18. Aurobindo Pharma
    • 13.2.19. Accord Healthcare
    • 13.2.20. Hospira (a Pfizer company)
    • 13.2.21. Teva Pharmaceutical Industries Ltd.
    • 13.2.22. Amneal Pharmaceuticals
    • 13.2.23. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us